Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Start feeling the excitement and check the programme for the latest updates
Advance your knowledge in this tumour type with the leaders in the field and get 2 ESMO-MORA category 1 points
Application deadline: 07 September 2022
Application deadline 17 August 2022
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
From the World Conference on Lung Cancer 2022:
Around a fifth of patients with thoracic cancer die within 30 days of COVID-19 infection but the risk is not predicted by recent receipt of systematic treatment for their malignancy
A focus on the latest research in targeting cancer microbiome
New anticancer drugs substantially reduce the risk of death and tumour progression, but only marginally extend patient survival
It is indicated for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%
Findings from the single-arm, phase II study
Findings from the TUXEDO-1 study
Findings from the ARCAGEN study (EORTC-1843)
Findings from an analysis of data from two ovarian cancer consortia
Genetic testing, along with assessment of clinical risk factors, could be used to identify survivors at high risk for severe obesity and associated cardio-metabolic complications
This radiopharmaceutical precursor must be used only for the radiolabelling of carrier medicines that have been specifically developed and authorised for radiolabelling with lutetium chloride
Findings from a comprehensive analysis of the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small cell lung cancer
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access
In this era of precision medicine, affordable profiling is essential
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
Two studies hint at a lack of effect of palbociclib on ovarian function and demonstrate similar reduced recurrence with abemaciclib regardless of menopausal status
New anticancer drugs substantially reduce the risk of death and tumour progression, but only marginally extend patient survival
It is indicated for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%
Findings from the single-arm, phase II study
Findings from the TUXEDO-1 study
Findings from the ARCAGEN study (EORTC-1843)
Findings from an analysis of data from two ovarian cancer consortia
Genetic testing, along with assessment of clinical risk factors, could be used to identify survivors at high risk for severe obesity and associated cardio-metabolic complications
This radiopharmaceutical precursor must be used only for the radiolabelling of carrier medicines that have been specifically developed and authorised for radiolabelling with lutetium chloride
Findings from a comprehensive analysis of the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small cell lung cancer
The ESMO World Congress on Gastrointestinal Cancer, the annual event dedicated to the presentation and discussion of new findings in GI cancer treatment, research and care, will be held as a fully onsite event in Barcelona, Spain, from 29 June to 2 July 2022.
Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.
The ESMO Gynaecological Cancers Congress 2022, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide insights into the latest treatments, biology and biomarkers of ovarian, uterine, cervical and rare cancers.
The evidence-based tool is designed to help interpret data from a heterogeneous research landscape
The ESMO Breast Cancer Congress 2022, the annual event dedicated to advancing the science, disseminating education and improving the practice of breast cancer specialists worldwide, will focus this year on integrating translational research for innovative clinical practice.
A consensus reached by a lung clinical community within the International Cancer Benchmarking Partnership (ICBP), presented at the ELCC, 30 March – 2 April 2022, has highlighted international disparities in management and outcomes of patients with lung cancer in high-income countries, and has provided a roadmap of key actions that should be taken to homogenise practices, help enable earlier diagnosis and offer equitable access to care.
More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five years, reveal real-world data from a Spanish national registry study reported at the European Lung Cancer Congress (ELCC), 30 March-2 April 2022.
The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting.
Original data presentations by the authors of the OlympiA and PEARLS/KEYNOTE-091 trials will be followed by critical analysis and discussion with a panel of renowned experts.
ESMO has announced today the winners of the 2022 ESMO Society Awards.
ESMO has announced today the results of its Executive Board elections following the closure of the voting system on Monday 27 June 2022.
ESMO has announced today that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine
ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
The 2022 ESMO Heine H. Hansen Award is conferred on Fred R. Hirsch for his lifelong outstanding contribution to lung cancer research
Who will be the next ESMO Awardees? Submit your nominations before 9 March.
Developed by the ESMO Precision Medicine Working Group, they provide guidance to medical oncologists on the use of circulating tumour DNA assays in clinical practice
The role of polygenic scores for stratified cancer prevention, and the genetic determinants for PSA levels to improve cancer screening utility will be debated during the sixth instalment in the World Cancer Report Updates webinar series.
This year, World Cancer Day is launching #CloseTheCareGap, a three-year campaign aiming to promote awareness, collaboration, and action for a more equitable future in cancer care.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on
With modest progress being made in the gender balance of the oncology field in recent years, women continue to be underrepresented in leadership positions despite making up an increasing proportion of the oncology workforce.
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Czech Republic
France
Republic of Singapore
Portugal
Switzerland
Republic of Singapore
Netherlands
Switzerland
Australia
Spain
Hungary
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2022 will be held on Saturday 10 September (17:30-20:00 CEST) during the ESMO Congress 2022 in Paris, France.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
